Do breast implants need replacement every 10 years? The date is not an expiration

Breast implants do not automatically expire at ten years. FDA says they are not lifetime devices and that the chance of complications and additional operations rises with time, but it also says an individual implant’s life cannot be predicted. The useful decision is not “Has year ten arrived?” It is “What does this exact implant, current examination, indicated imaging, symptoms, and the person’s goals support now?”¹²

Ten-year follow-up tables are often converted into an expiration date they were never designed to create. They describe what happened to a group over a stated period. They do not make every intact, acceptable implant fail on the same anniversary, and they do not guarantee that a younger implant has no problem.

“Not lifetime” and “replace at ten” are different claims

FDA’s statement that breast implants are not lifetime devices is a warning against assuming one operation ends all future care.¹ It means a person should anticipate monitoring, possible complications, and the possibility of revision, removal, or replacement over a lifetime.

A fixed ten-year rule would mean time alone is an indication for surgery. FDA does not state that rule. Current product labeling instead gives risks, device-specific study data, follow-up instructions, and—for silicone gel implants—rupture-screening recommendations.³⁴ The treating clinicians still interpret those records in the context of the person and the implant.

The implant record comes before the replacement quote

“Breast implant” is not a sufficient device identity. Retrieve the patient device card or operative report and record:

• manufacturer, product line, fill material, surface, shape, and size;
• left and right serial or lot information when available;
• operation date, incision, pocket plane, and any mesh or other material;
• whether the operation was augmentation, reconstruction, or revision;
• later imaging, symptoms, procedures, and adverse-event reports; and
• the current patient labeling and any product-specific safety action.

FDA maintains current labeling and approval records for marketed saline- and silicone-gel implants.³ A ten-year-old label screenshot is not necessarily the current record, and one manufacturer’s study cannot be applied to a different model without saying so.

Surveillance is not scheduled replacement

Silicone gel can rupture without an obvious change. FDA’s labeling recommendations call for the first ultrasound or MRI for rupture screening in an asymptomatic patient at five to six years after surgery and every two to three years after that; MRI is recommended for symptoms or an equivocal ultrasound.⁴ That is a surveillance schedule, not an instruction to exchange an intact implant at the first or tenth scan.

Saline rupture is commonly apparent through deflation, so the same silent-rupture screening language does not apply. Breast-cancer screening is also a separate job from implant-integrity surveillance. The MRI-versus-ultrasound guide keeps those pathways distinct.

If an imaging report says “intact,” “possible rupture,” “intracapsular rupture,” or “extracapsular silicone,” preserve the exact wording and images. The report informs the surgical discussion; it does not choose a procedure by itself.

Reasons to reassess do not all lead to the same operation

FDA lists complications including rupture or deflation, capsular contracture, pain, infection, asymmetry, scarring, and the need for reoperation or removal.² New swelling, a mass, hardening, persistent pain, skin change, a sudden size change, or another concern deserves an appropriate clinical route rather than waiting for an anniversary.

The resulting plan might involve observation, more imaging, implant exchange, implant removal without replacement, a lift, pocket work, or capsule sampling or removal. Those are not synonyms. The implant-removal and capsulectomy guide explains why “total,” “intact,” and “en bloc” describe different concepts.

Certain symptoms can also require a diagnosis-specific pathway. A late fluid collection or mass should not be reduced to “old implant.” The BIA-ALCL and capsule-SCC guide explains the separate sampling and pathology questions.

Compare continued surveillance with an operation on one horizon

An elective replacement quote should be evaluated against the alternative of keeping the current device under a documented follow-up plan. Use the same horizon for both:

Do not let “upgrade,” “refresh,” or “warranty” replace the clinical and contractual records. A warranty may cover a defined device under stated conditions; it does not decide whether surgery is indicated or pay every associated cost.

A useful ten-year visit produces a plan, not a countdown

1. Recover the exact device record. Match the card and operative report to current FDA labeling, approval history, and any manufacturer notice.
2. Separate the three screening jobs. Keep implant-integrity surveillance, symptom evaluation, and breast-cancer screening on their own schedules.
3. Document change over time. Bring prior images and reports and describe new pain, firmness, swelling, size, shape, skin, or systemic concerns without assigning a cause.
4. Name the proposed operation. Require the quote and consent to distinguish exchange, removal, lift, pocket work, and the planned extent and reason for any capsule procedure.
5. Define the alternative and trigger points. If surgery is not planned now, record the follow-up interval, symptom route, imaging ownership, and findings that would reopen the decision.

A calendar date should never stand alone as the reason to operate. The record should name the product-specific finding, symptom, preference, or current label that supports action now—and the documented surveillance plan if none does.